ICBAS - Instituto de Ciências Biomédicas Abel Salazar, UMIB-Unidade Multidisciplinar de Investigação Biomédica, Universidade Do Porto, Porto, Portugal.
ITR-Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal.
Acta Diabetol. 2023 Aug;60(8):1019-1026. doi: 10.1007/s00592-023-02092-1. Epub 2023 Apr 21.
To evaluate the accuracy of DiaBetter, DiaRem, Ad-DiaRem and 5y-Ad-DiaRem scores' at predicting T2D remission 10 or more years after surgery.
Patients with obesity and T2D (n = 126) submitted to RYGB with 10 or more years of follow-up. It was a unicentric trial. Pre-operative anthropometric and clinical data was retrieved to calculate DiaRem, DiaBetter, Ad-DiaRem and 5y-Ad-DiaRem scores, while a hospital visit was conducted to assess current diabetes status. The area under the receiver operating characteristic (AUROC) curve was calculated as estimate of the scores' accuracy to predict long-term T2D remission.
Among the entire cohort (n = 126), 70 subjects (55.6%) achieved and maintained T2D remission 10 or more years after RYGB. The 5y-Ad-DiaRem score was the one that depicted the highest discriminative power (AUROC = 0.838) to predict long-term T2D remission when compared to DiaBetter (AUROC = 0.735), DiaRem (AUROC = 0.721) and Ad-DiaRem (AUROC = 0.720).
The score with highest accuracy to predict long-term T2D remission after RYGB surgery was the 5y-Ad-DiaRem. Yet, the available scores accuracy to predict T2D remission in the long term is still suboptimal, highlighting the unmet need for a better scoring system.
评估 DiaBetter、DiaRem、Ad-DiaRem 和 5y-Ad-DiaRem 评分在预测手术后 10 年以上 T2D 缓解的准确性。
对肥胖和 T2D 患者（n=126）进行 RYGB 手术，并进行 10 年以上的随访。这是一项单中心试验。回顾性收集术前的人体测量和临床数据，以计算 DiaRem、DiaBetter、Ad-DiaRem 和 5y-Ad-DiaRem 评分，同时进行一次医院就诊以评估当前的糖尿病状况。接受者操作特征曲线（AUROC）下面积被计算为评分预测长期 T2D 缓解的准确性估计。
在整个队列（n=126）中，70 名患者（55.6%）在 RYGB 后 10 年或更长时间内实现并维持 T2D 缓解。与 DiaBetter（AUROC=0.735）、DiaRem（AUROC=0.721）和 Ad-DiaRem（AUROC=0.720）相比，5y-Ad-DiaRem 评分对预测长期 T2D 缓解的区分能力最高（AUROC=0.838）。
预测 RYGB 术后长期 T2D 缓解的准确性最高的评分是 5y-Ad-DiaRem。然而，目前预测 T2D 缓解的评分准确性仍然不够理想，突出了对更好评分系统的需求。
